T

Talkmed Group Ltd
SGX:5G3

Watchlist Manager
Talkmed Group Ltd
SGX:5G3
Watchlist
Price: 0.44 SGD -2.22% Market Closed
Market Cap: 584.2m SGD
Have any thoughts about
Talkmed Group Ltd?
Write Note

Talkmed Group Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Talkmed Group Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
T
Talkmed Group Ltd
SGX:5G3
Income from Continuing Operations
S$25.5m
CAGR 3-Years
2%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Cordlife Group Ltd
SGX:P8A
Income from Continuing Operations
-S$11m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Q & M Dental Group (Singapore) Ltd
SGX:QC7
Income from Continuing Operations
S$11.1m
CAGR 3-Years
-18%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Healthway Medical Corporation Ltd
SGX:5NG
Income from Continuing Operations
S$8.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-11%
HC Surgical Specialists Ltd
SGX:1B1
Income from Continuing Operations
S$3.9m
CAGR 3-Years
-24%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
EUDA Health Holdings Ltd
NASDAQ:EUDA
Income from Continuing Operations
-$8.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Talkmed Group Ltd
Glance View

Market Cap
583.7m SGD
Industry
Health Care

TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).

5G3 Intrinsic Value
0.31 SGD
Overvaluation 30%
Intrinsic Value
Price
T

See Also

What is Talkmed Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
25.5m SGD

Based on the financial report for Jun 30, 2024, Talkmed Group Ltd's Income from Continuing Operations amounts to 25.5m SGD.

What is Talkmed Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-4%

Over the last year, the Income from Continuing Operations growth was -15%. The average annual Income from Continuing Operations growth rates for Talkmed Group Ltd have been 2% over the past three years , -4% over the past five years .

Back to Top